Market Overview

UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise

Related HOLX
Adoption Of 3D Mammography Appears To Be On The Cusp Of An Inflection
Benzinga's Top Upgrades, Downgrades For February 15, 2017
VentriPoint Diagnostics (VPTDF, CVE:VPT) Just Put Imaging Names Like Hologic (HOLX) and Analogic (ALOG) on Notice (Small Cap Network)

ISI Group maintained Hologic (NASDAQ: HOLX) with a Strong Buy rating and raised the price target from $25.50 to $27.00.

ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00."

Hologic closed at $23.25 on Monday.

Latest Ratings for HOLX

Feb 2017NeedhamUpgradesHoldBuy
Feb 2017Bank of AmericaDowngradesBuyNeutral
Jan 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!